This article introduces MITO-ONC-RX, a mitochondrial-based oncology platform designed to target cancer stem cells (CSCs). The platform focuses on disrupting the metabolic and mitochondrial functions essential for CSC survival and proliferation. The study highlights MITO-ONC-RX as a promising therapeutic strategy to target CSCs, which are known for their role in
